MedTrace Logo

BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment

NCT03361111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2019-10-11

No results posted yet for this study

Summary

Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expressed genes in epithelial cells and lung fibroblasts in asthma. Omalizumab is approved as add-on therapy in the treatment of severe allergic asthma. The aim of the study is to assess inflammatory biomarkers including: blood and sputum eosinophilia, periostin and IL-6 as long-term clinical outcomes of omalizumab therapy.

Conditions

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Joanna Hermanowicz-Salamon, MD,PhD · Department of Internal Medicine, Pulmonary Diseases and Allergy Medical University of Warsaw, Poland

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-04
Primary Completion
2018-11-05
Completion
2018-12-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03361111 on ClinicalTrials.gov